Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Receivables (2016 - 2025)

Historic Receivables for Corcept Therapeutics (CORT) over the last 10 years, with Q3 2025 value amounting to $73.5 million.

  • Corcept Therapeutics' Receivables rose 2312.91% to $73.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.5 million, marking a year-over-year increase of 2312.91%. This contributed to the annual value of $54.0 million for FY2024, which is 2604.44% up from last year.
  • Latest data reveals that Corcept Therapeutics reported Receivables of $73.5 million as of Q3 2025, which was up 2312.91% from $68.7 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Receivables registered a high of $80.0 million during Q1 2025, and its lowest value of $23.9 million during Q1 2021.
  • For the 5-year period, Corcept Therapeutics' Receivables averaged around $46.5 million, with its median value being $46.6 million (2023).
  • Its Receivables has fluctuated over the past 5 years, first tumbled by 1489.82% in 2021, then surged by 6522.46% in 2023.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Receivables stood at $27.6 million in 2021, then soared by 63.1% to $45.1 million in 2022, then decreased by 4.96% to $42.8 million in 2023, then soared by 35.62% to $58.1 million in 2024, then grew by 26.61% to $73.5 million in 2025.
  • Its Receivables was $73.5 million in Q3 2025, compared to $68.7 million in Q2 2025 and $80.0 million in Q1 2025.